Humana (NYSE:HUM) Given a $268.00 Price Target by Barclays Analysts

Humana (NYSE:HUM) received a $268.00 price target from equities researchers at Barclays in a report issued on Thursday, MarketBeat Ratings reports. The brokerage currently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s target price would indicate a potential upside of 15.32% from the company’s current price.

Several other brokerages also recently issued reports on HUM. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Mizuho raised their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $284.24.

Humana Stock Down 1.2%

HUM stock traded down $2.87 during mid-day trading on Thursday, hitting $232.39. The stock had a trading volume of 684,440 shares, compared to its average volume of 1,789,944. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 1-year low of $212.45 and a 1-year high of $406.46. The company has a fifty day moving average of $250.43 and a 200 day moving average of $262.41. The stock has a market capitalization of $28.05 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 2.05 and a beta of 0.43.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $7.23 EPS. On average, equities analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Humana

Several institutional investors have recently modified their holdings of the stock. FPC Investment Advisory Inc. bought a new position in shares of Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana during the fourth quarter worth about $30,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares during the period. LFA Lugano Financial Advisors SA raised its position in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. Finally, OFI Invest Asset Management acquired a new stake in shares of Humana during the fourth quarter worth about $33,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.